DURECT Corporation stock is up 30.77% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 23 March’s closed higher than February.
DURECT Corporation researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!